| Trial ID: | L1706 |
| Source ID: | NCT06659718
|
| Associated Drug: |
Oral Semaglutide
|
| Title: |
Emulation of the SOUL Diabetes Trial in Healthcare Claims
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Oral semaglutide|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Major adverse cardiac event (MACE), including myocardial infarction, stroke and all cause death, Hazard ratio, Through study completion (1 day after cohort entry date until the first of outcome or censoring) | Other: Cataract surgery (negative control), Hazard ratio, Through study completion (1 day after cohort entry date until the first of outcome or censoring)
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
43650
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2024-10-24
|
| Completion Date: |
2024-12
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-20
|
| Locations: |
Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06659718
|
